Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid

Journal of Laboratory and Clinical Medicine

Volumn 138, Issue 4, 2001, Pages 257-269

  Dasgupta, Arunansu ^a,b   Ramaswamy, Kumaraswamy ^a,b   Giraldo, Jorge ^a,b   Taniguchi, Masato ^a,b   Amenta, Peter S ^a,b   Das, Kiron M ^a,b  

^a Current affiliations: Department of Medicine   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034808748     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.118221     Document Type: Article

References (43)

1. The regulation of immune responses to dietary protein antigens
2. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
3. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
4. Effects of oral administration of type II collagen on rheumatoid arthritis
5. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis
6. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial
7. Peripheral deletion of antigen-reactive T cells in oral tolerance
8. The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation
9. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage
10. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain
11. Inflammatory bowel disease
12. Autoimmunity and ulcerative colitis: Can two enigmas make sense together?
13. Relationships of extracolonic involvement in inflammatory bowel disease: New insights into autoimmune pathogenesis
14. A shared and unique epitope(s) on human colon, skin and biliary epithelium detected by a monoclonal antibody
15. A shared a unique peptide in human colon, eye and joint detected by a novel monoclonal antibody
16. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
17. Spontaneous inflammatory disease in transgenic rats expressing HLA B27 and human β2m: An animal model of HLAB-27-associated human disorders
18. Interleukin 10 deficient mice develop chronic enterocolitis
19. Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease
20. Severe colitis in mice with aberrant thymic selection
21. Hapten-induced model of chronic inflammation and ulceration in the rat colon
22. Hapten-induced model of murine inflammatory bowel disease: Mucosal immune responses and protection by tolerance
23. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance
24. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
25. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
26. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice
27. Peroxidase
28. Treatment of experimental colitis by oral tolerance induction: A central role for suppressor lymphocytes
29. Oral administration of unmodified colonic but not small intestinal antigens protects rats from hapten-induced colitis
30. The role of luminal bacteria in colitis: More than an antigenic drive
31. Production of immunity and unresponsiveness in the mouse by feeding contact sensitizing agents and the role of suppressor cells in the Peyer's patches, mesenteric lymph nodes and other lymphoid tissues
32. T lymphocyte sub-populations and immunoglobulin-containing cells in the colonic mucosa of ulcerative colitis: A morphometric and immunohistochemical study
33. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis
34. Expression of class II molecules on intestinal epithelial cells in humans
35. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound IgC from idiopathic ulcerative colitis
36. Autoimmunity to cytoskeletal protein tropomyosin(s): A new clue to the pathogenetic mechanism for ulcerative colitis
37. Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis
38. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives
39. Autoantibodies against the specific epitope of human tropomyosin(s) detected by a peptide based enzyme immunoassay in sera of patients with ulcerative colitis show antibody dependent cell mediated cytotoxicity against HLA-DPw9 transfected L cells
40. Externalization of tropomyosin isoform 5 in colon epithelial cells
41. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment
42. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis
43. Transforming growth factor-β1 is a costimulator for IgA production